Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts
Stopped Due to the termination criteria for dose escalation in the clinical protocol having been reached, this trial is terminated.
Conditions
Interventions
- DRUG: SZEY-2108 for injetion
- DRUG: Placebo
Sponsor
Suzhou Erye Pharmaceutical Co., Ltd.